Jeff Sharman, Medical Director of Hematology Research at Sarah Cannon Research Institute, shared a post on LinkedIn by David R. Spigel, Chief Scientific Officer of Sarah Cannon Research Institute, adding:
“It used to be that research only emerged from the most esteemed academic institutions. Proud to help prove that groundbreaking research can be done in the community oncology setting – bringing research right to the places where patients receive their care. This year at ASH – our network was prolific!”
Quoting David R. Spigel’s post:
“With contributions from more than 50 investigators, our Sarah Cannon Research Institute network will deliver 100 abstracts and presentations across leukemia, lymphoma, Β-thalassemia, and sickle cell disease at this year’s American Society of Hematology Annual Meeting, marking our largest presence to date.
This level of collaboration reflects what defines SCRI: bringing high-quality, patient-centered research directly into the communities we serve, and creating more opportunities for patients to access cutting-edge clinical science.
I’m looking forward to reviewing this year’s data at hashtag#ASH25 and seeing how these insights will inform the next era of progress in hematologic research and care.
Learn more about our presence at this year’s meeting here.”
More posts featuring Jeff Sharman.